مباشر

FierceBiotechNovo reports data breach, tells clinical trial patients to 'remain vigilant'Endpoints NewsThe seeming inevitability of rising healthcare costs FierceBiotechPredicta links with Spanish university to offer diagnostic for blood cancers BioPharma DiveSummit pulls $500M share sale a day after announcing it Endpoints NewsDrugmakers are turning to logistics providers as trade disruptions linger, DHL exec says BioPharma DiveSensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy Endpoints NewsSummit withdraws $500M offering, citing 'market conditions'BioWorldScore in phase I CML trial has Enliven looking ahead to phase III Clinical OMICsLipid-Protein Biomarker Makes Clinical Debut with Early Ovarian Cancer Detection Endpoints NewsSensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophy Endpoints NewsCamurus’ second CRL for acromegaly drug; Teva details workforce cuts FierceBiotechFierce Biotech heading to UK to host event amid London Life Sciences Week

BioWorld ١١ يونيو ٢٠٢٦

Innovo Therapeutics synthesizes new NMT1 inhibitors

Innovo Therapeutics Inc. has divulged sulfonamide derivatives acting as N-myristoyltransferase 1 (NMT1) inhibitors found to be potentially useful for the treatm...

Innovo Therapeutics Inc. has divulged sulfonamide derivatives acting as N-myristoyltransferase 1 (NMT1) inhibitors found to be potentially useful for the treatment of cancer, protozoal and viral infection.